Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedDec 05, 2025
DataAggregated Company Financials
Companies21
  • 7D-1.2%
  • 3M-8.8%
  • 1Y-53.2%
  • YTD-44.6%

Over the last 7 days, the Healthcare industry has dropped 2.8%, driven by Novo Nordisk declining 1.6%. However, the industry is down 54% over the past year. Earnings are forecast to grow by 4.9% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 05 Dec 2025DKK 1.9tDKK 454.0bDKK 136.9b17x13.6x4.1x
Sun, 02 Nov 2025DKK 1.9tDKK 448.0bDKK 141.9b17.2x13.4x4.3x
Tue, 30 Sep 2025DKK 2.0tDKK 447.4bDKK 141.7b18x14.4x4.6x
Thu, 28 Aug 2025DKK 2.1tDKK 447.6bDKK 141.8b24.3x14.5x4.6x
Sat, 26 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.1x19.9x5.9x
Mon, 23 Jun 2025DKK 2.6tDKK 423.5bDKK 124.6b30.4x20.6x6.1x
Wed, 21 May 2025DKK 2.5tDKK 424.3bDKK 125.1b24.1x19.9x5.9x
Fri, 18 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.8x19.1x5.7x
Sun, 16 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.9x23.5x7x
Tue, 11 Feb 2025DKK 3.3tDKK 408.3bDKK 118.3b28.4x27.6x8x
Thu, 09 Jan 2025DKK 3.3tDKK 387.5bDKK 111.3b29.9x29.6x8.5x
Sat, 07 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.3x36.3x10.4x
Mon, 04 Nov 2024DKK 4.0tDKK 372.2bDKK 107.2b34.5x37.1x10.7x
Wed, 02 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.4x11.1x
Fri, 30 Aug 2024DKK 4.7tDKK 371.8bDKK 107.1b33.8x44.1x12.7x
Sun, 28 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b35.9x42.1x12.6x
Tue, 25 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b34.8x46.7x14x
Thu, 23 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.9x44.1x13.2x
Sat, 20 Apr 2024DKK 4.4tDKK 341.3bDKK 99.6b32.8x44.3x12.9x
Mon, 18 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.3x46.5x13.6x
Wed, 14 Feb 2024DKK 4.3tDKK 340.5bDKK 98.6b34.4x43.3x12.5x
Fri, 12 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.8x42.1x11.8x
Sun, 10 Dec 2023DKK 3.5tDKK 320.6bDKK 90.0b33.8x38.9x10.9x
Tue, 07 Nov 2023DKK 3.6tDKK 318.7bDKK 90.3b29.2x40x11.3x
Thu, 05 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b32.5x40.9x11x
Sat, 02 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b36.7x42x11.3x
Mon, 31 Jul 2023DKK 2.9tDKK 287.2bDKK 75.5b37.2x38.5x10.1x
Wed, 28 Jun 2023DKK 3.0tDKK 287.0bDKK 75.5b38.6x39.2x10.3x
Fri, 26 May 2023DKK 3.1tDKK 287.1bDKK 75.5b41.2x40.9x10.8x
Sun, 23 Apr 2023DKK 3.2tDKK 272.6bDKK 68.5b44x46.7x11.7x
Tue, 21 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b37.7x39.9x9.4x
Thu, 16 Feb 2023DKK 2.8tDKK 289.4bDKK 68.9b40.2x40.6x9.7x
Sat, 14 Jan 2023DKK 2.7tDKK 276.0bDKK 66.3b38.4x40.3x9.7x
Mon, 12 Dec 2022DKK 2.7tDKK 276.1bDKK 66.3b38.5x40.2x9.7x
Price to Earnings Ratio

40.2x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 66.3bTotal Revenue: DKK 276.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 34.7x202320242025
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 13.5x which is lower than its 3-year average PE of 34.7x.
  • The 3-year average PS ratio of 9.7x is higher than the industry's current PS ratio of 4.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.30%
Healthcare-1.22%
Biotech0.60%
Medical Equipment-0.18%
Pharma-1.55%
Healthtech-3.07%
Life Sciences-3.70%
Healthcare Services-9.65%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 71.6x.
    • Analysts are expecting annual earnings growth of 81.0%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 94% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 16% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 2.06k1.5%
+DKK 1.9b		32.9%PE12.5x
EMBLA Embla Medical hfDKK 37.206.0%
+DKK 897.7m		1.6%PE32.2x
BAVA Bavarian NordicDKK 191.853.5%
+DKK 500.9m		-0.4%PE6.1x
HLUN B H. LundbeckDKK 44.501.0%
+DKK 436.1m		0.4%PE11.6x
COLO B ColoplastDKK 585.200.2%
+DKK 225.4m		-33.2%PE36.3x

Latest News

COLO B
DKK 585.20
Coloplast
7D
0.2%
1Y
-33.2%
NOVO B
DKK 305.80
Novo Nordisk
7D
-1.6%
1Y
-60.3%
EMBLA
DKK 37.20
Embla Medical hf
7D
6.0%
1Y
1.6%

Here's Why We Think Embla Medical hf (CPH:EMBLA) Is Well Worth Watching

Dec 04
Here's Why We Think Embla Medical hf (CPH:EMBLA) Is Well Worth Watching
DEMANT
DKK 213.20
Demant
7D
-2.6%
1Y
-22.2%
BAVA
DKK 191.85
Bavarian Nordic
7D
3.5%
1Y
-0.4%

BAVA: Procurement Agreement And Margin Outlook Signal Upside For Shares

Analysts have raised their price target for Bavarian Nordic from €250 to €260. They cite improvements in projected profit margins and lower expected future price-to-earnings ratios, even though there is a modest increase in the discount rate and a slightly weaker revenue growth outlook.
HLUN B
DKK 44.50
H. Lundbeck
7D
1.0%
1Y
0.4%
ALK B
DKK 229.40
ALK-Abelló
7D
-1.1%
1Y
40.6%
VIRO
DKK 15.65
ViroGates
7D
-2.2%
1Y
5.7%
GMAB
DKK 2,062.00
Genmab
7D
1.5%
1Y
32.9%

GMAB: Merus Acquisition and Pipeline Depth Will Shape Market Outlook

Genmab's analyst price target has seen a modest decrease of approximately DKK 3.57 to DKK 2,054.66. Analysts are factoring in sustaining growth drivers from recent pipeline acquisitions while adjusting for updates to discount rate and margin assumptions.
AMBU B
DKK 86.95
Ambu
7D
-1.2%
1Y
-22.0%
ZEAL
DKK 505.80
Zealand Pharma
7D
-3.8%
1Y
-33.1%

ZEAL: Future Discount Rate Shift Will Unlock Undervalued Potential

Analysts have revised Zealand Pharma's price target downward from $818.80 to $793.06. This adjustment primarily reflects reduced growth expectations and a slightly higher discount rate in their updated models.
BIOPOR
DKK 1.15
BioPorto
7D
7.1%
1Y
-36.0%
NNIT
DKK 49.90
NNIT
7D
-3.3%
1Y
-45.5%
GUBRA
DKK 483.20
Gubra
7D
-2.9%
1Y
-31.4%
CHEMM
DKK 749.50
ChemoMetec
7D
-4.2%
1Y
54.5%
MONSO
DKK 0.19
Monsenso
7D
17.8%
1Y
-52.9%